Stock 4568 DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Daiichi Sankyo Co., Ltd. Stock

Equities

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 01:30:00 2024-12-13 am EST 		5-day change 1st Jan Change
4,310.00 JPY -3.12% Intraday chart for Daiichi Sankyo Co., Ltd. -7.95% +11.31%
Dec. 10 Quantum-Wild Phase 3 Trial of VANFLYTA Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML CI
Dec. 09 Astrazeneca, Daiichi Sankyo's Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US MT

Valuation: Daiichi Sankyo Co., Ltd.

Capitalization 8,118B 52.83B 50.33B 47.19B 41.85B 75.21B 4,481B 83.13B 580B 215B 1,846B 199B 194B P/E ratio 2025 *
36.4x
P/E ratio 2026 * 31x
Enterprise value 7,294B 47.46B 45.22B 42.4B 37.6B 67.57B 4,026B 74.69B 521B 193B 1,659B 178B 174B EV / Sales 2025 *
3.97x
EV / Sales 2026 * 3.47x
Free-Float
96.08%
Yield 2025 *
1.43%
Yield 2026 * 1.67%
More valuation ratios * Estimated data

Chart: Daiichi Sankyo Co., Ltd.

Dynamic Chart

Latest news: Daiichi Sankyo Co., Ltd.

Quantum-Wild Phase 3 Trial of VANFLYTA Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML Dec. 10 CI
Astrazeneca, Daiichi Sankyo's Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US Dec. 09 MT
AstraZeneca, Daiichi Sankyo hail US breakthrough therapy designation Dec. 09 AN
Boohoo gets ISS backing amid Frasers Group spat Dec. 09 AN
AstraZeneca, Daiichi Sankyo's Lung Cancer Treatment Receives Breakthrough Designation from US FDA Dec. 09 MT
Datopotamab Deruxtecan Grants Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Dec. 09 CI
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced Egfr-Mutated Non-Small Cell Lung Cancer in Tropion-Lung01 Pooled Analysis Dec. 05 CI
Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers At Esmo Asia, Sabcs and Ash Dec. 01 CI
AstraZeneca's Enhertu included in China's state insurance reimbursement Nov. 28 RE
AstraZeneca "disappointed" as breast cancer drug blocked for NHS use Nov. 19 AN
GRAIL Says First Person Tested With Blood-Based Assay in Lung Cancer Trial Nov. 18 MT
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study Nov. 18 CI
Daiichi Sankyo to Showcase TURALIO Research in Patients with Tenosynovial Giant Cell Tumor at CTOS Nov. 13 CI
More news

Last Transcript: Daiichi Sankyo Co., Ltd.

Logo Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Company, Limited, Q2 2025 Earnings Call, Oct 31, 2024
Oct. 31
More transcripts

Analysts' recommendations: Daiichi Sankyo Co., Ltd.

Jefferies Adjusts Daiichi Sankyo's Price Target to 7,600 Yen From 6,600 Yen, Keeps at Buy Sep. 04 MT
Jefferies Adjusts Daiichi Sankyo’s Price Target to 6,600 Yen From 5,600 Yen, Keeps at Buy May. 24 MT
Jefferies Adjusts Daiichi Sankyo’s Price Target to 5,600 Yen From 4,800 Yen, Keeps at Buy Feb. 21 MT
Jefferies Upgrades Daiichi Sankyo to Buy From Hold, Adjusts Price Target to 4,800 Yen From 4,300 Yen Dec. 04 MT
Jefferies Adjusts Daiichi Sankyo’s Price Target to 4,300 Yen From 3,900 Yen, Keeps at Hold 23-10-23 MT
More recommendations

Press Releases: Daiichi Sankyo Co., Ltd.

QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML Dec. 10 BU
Daiichi Sankyo : Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR Mutated Non Small Cell Lung Cancer Dec. 09 PU
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer Dec. 09 BU
Daiichi Sankyo : Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR Mutated Non Small Cell Lung Cancer in TROPION Lung05 and TROPION Lung01 Pooled Analysis Dec. 05 PU
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis Dec. 05 BU
More press releases

News in other languages: Daiichi Sankyo Co., Ltd.

MÄRKTE ASIEN/Sorgen vor Handelskonflikt mit USA belastet Nov. 13
AstraZeneca : sollicite la FDA dans le cancer du poumon Nov. 12
Merck publie des résultats contrastés au troisième trimestre Oct. 31
MÄRKTE USA/Börsen mit leichten Aufschlägen Sep. 17
Merck : succès d'un essai de phase 3 dans le cancer du sein Sep. 17
More news

Quotes and Performance

1 day-3.12%
1 week-7.95%
Current month-9.24%
1 month-6.79%
3 months-16.07%
6 months-22.97%
Current year+11.31%
More quotes

Course Extremes

1 week
4 262.00
Extreme 4262
4 676.00
1 month
4 262.00
Extreme 4262
4 951.00
Current year
3 847.00
Extreme 3847
6 257.00
1 year
3 805.00
Extreme 3805
6 257.00
3 years
2 288.00
Extreme 2288
6 257.00
5 years
1 731.00
Extreme 1731
6 257.00
10 years
518.67
Extreme 518.6667
6 257.00
More quotes

Managers and Directors: Daiichi Sankyo Co., Ltd.

Director TitleAgeSince
Sunao Manabe CEO
 Chief Executive Officer 70 2019-05-31
Hiroyuki Okuzawa DFI
 Director of Finance/CFO 62 2021-06-20
Takashi Matsumoto HRO
 Human Resources Officer 60 2019-03-31
Manager TitleAgeSince
Sunao Manabe CHM
 Chairman 70 2023-03-31
Kazuaki Kama BRD
 Director/Board Member 76 2019-05-31
Sawako Nohara BRD
 Director/Board Member 66 2019-05-31
More insiders

ETFs: Daiichi Sankyo Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY ETF Nomura NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY
25.16% 16 M€ +7.40%
NEXT FUNDS SOLACTIVE JAPAN ESG CORE INDEX ETF - JPY ETF NEXT FUNDS Solactive Japan ESG Core Index ETF - JPY
4.18% 247 M€ +20.10%
LYXOR MSCI JAPAN ESG LEADERS EXTRA (DR) UCITS ETF - ACC - EUR ETF Lyxor MSCI Japan ESG Leaders Extra (DR) UCITS ETF - Acc - EUR
3.32% 174 M€ -.--% -
LYXOR MSCI JAPAN ESG LEADERS EXTRA (DR) UCITS ETF - DAILY HEDGED TO EUR - ACC - EUR ETF Lyxor MSCI Japan ESG Leaders Extra (DR) UCITS ETF - Daily Hedged to EUR - Acc - EUR
3.32% 51 M€ -.--% -
NEXT FUNDS MSCI JAPAN COUNTRY ESG LEADERS INDEX EXCHANGE TRADED FUND - JPY ETF NEXT FUNDS MSCI Japan Country ESG Leaders Index Exchange Traded Fund - JPY
3.24% 15 M€ +20.04%
More ETFs: Daiichi Sankyo Co., Ltd.

Other Pharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
DAIICHI SANKYO CO., LTD. Stock Daiichi Sankyo Co., Ltd.
-3.12%-7.95%+6.16%+52.65%52.83B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+0.87%-4.55%+32.07%+217.51%711B
NOVO NORDISK A/S Stock Novo Nordisk A/S
-3.89%-4.01%+12.24%+97.87%469B
JOHNSON & JOHNSON Stock Johnson & Johnson
+0.26%-1.80%-5.89%-12.96%353B
ABBVIE INC. Stock AbbVie Inc.
+0.10%-1.60%+12.36%+37.04%306B
MERCK & CO., INC. Stock Merck & Co., Inc.
+0.74%-1.06%-4.77%+38.93%258B
ROCHE HOLDING AG Stock Roche Holding AG
-0.90%-1.48%+0.22%-32.53%228B
ASTRAZENECA PLC Stock AstraZeneca PLC
-0.95%-1.75%+0.75%+26.92%205B
NOVARTIS AG Stock Novartis AG
-0.36%-2.30%+1.19%+17.71%196B
AMGEN INC. Stock Amgen Inc.
-1.26%-0.72%-3.91%+28.02%145B
Average -1.04%-2.66%+5.04%+47.12% 292.45B
Weighted average by Cap. -0.75%-2.77%+9.99%+77.20%
See all sector performances

Financials

2025 *2026 *
Net sales 1,833B 11.93B 11.37B 10.66B 9.45B 16.99B 1,012B 18.77B 131B 48.47B 417B 44.83B 43.83B 2,076B 13.51B 12.87B 12.07B 10.7B 19.24B 1,146B 21.26B 148B 54.89B 472B 50.77B 49.63B
Net income 225B 1.46B 1.39B 1.31B 1.16B 2.08B 124B 2.3B 16.06B 5.94B 51.1B 5.49B 5.37B 263B 1.71B 1.63B 1.53B 1.35B 2.43B 145B 2.69B 18.77B 6.94B 59.73B 6.42B 6.28B
Net Debt -825B -5.37B -5.11B -4.79B -4.25B -7.64B -455B -8.44B -58.94B -21.8B -188B -20.16B -19.71B -879B -5.72B -5.45B -5.11B -4.53B -8.15B -485B -9B -62.85B -23.24B -200B -21.5B -21.02B
More financial data * Estimated data

Company Profile

Logo Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.9%): prescription medicines (95.3% of net sales) and OTC medicines (4.7%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.1%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (37.4%), North America (31.2%), Europe (19.4%) and other (12%).
Employees
18,726
Sector
Pharmaceuticals
Calendar
2024-12-16 - R&D Day
More about the company

Quotes

Date Price Change Volume
24-12-13 4,310.00 ¥ -3.12% 8,728,100
24-12-12 4,449.00 ¥ +0.34% 4,517,600
24-12-11 4,434.00 ¥ -1.51% 6,867,000
24-12-10 4,502.00 ¥ -1.92% 6,011,200
24-12-09 4,590.00 ¥ -1.96% 3,801,500

Delayed Quote Japan Exchange, December 13, 2024 at 01:30 am EST

More quotes

Income Statement and Estimates

income-statement-evolution-chart DAIICHI-SANKYO-CO-LTD More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
A-
surperformance-ratings-light-chart DAIICHI-SANKYO-CO-LTDMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
4,310.00JPY
Average target price
6,333.33JPY
Spread / Average Target
+46.95%
Consensus
Profit revisions
estimates-change-chart DAIICHI-SANKYO-CO-LTD Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart DAIICHI-SANKYO-CO-LTD Company calendar
  1. Stock Market
  2. Equities
  3. 4568 Stock